Finally, we substantiated that RRM2 could cause cisplatin resistance in BLCA, suggesting that targeting RRM2 may enhance chemotherapy sensitivity in BLCA patients (Figure 10G–H). The gene discussed is RRM2; the disease is bladder transitional cell carcinoma.